Web

  • http://www.drugs.com/mtm/denosumab.html
  • Denosumab is a monoclonal antibody.Monoclonal antibodies are made to target and destroy only certain cells in the body.
  • http://www.medicines.org.uk/emc/medicine/23127
  • Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology.
  • http://www.netdoctor.co.uk/medicines/aches-and-pains/a8761/prolia...
  • Prolia injection contains the active ingredient denosumab, which is a type of medicine called a human monoclonal antibody.
  • http://www.wikidoc.org/index.php/Denosumab
  • WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling.
  • http://www.cancer.gov/about-cancer/treatment/drugs/denosumab/
  • This page contains brief information about denosumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
  • http://www.uwhealth.org/health/topic/multum/prolia/d07640a1.html
  • This medication guide provides information about the Prolia brand of denosumab.
  • http://www.nps.org.au/medicines/hormonal-and-metabolic-system/cal...
  • Prolia Solution for injection is a brand of medicine containing the active ingredient denosumab (calcium and bone metabolism medicines).
  • http://www.diagnosia.com/en/drug/prolia-60-mg-solution-injection
  • What Prolia is and how it worksProlia contains denosumab, a protein (monoclonal antibody) that interferes with the action of another protein, in order to treat bone loss and osteoporosis.
  • http://chemocare.com/chemotherapy/drug-info/denosumab.aspx
  • Denosumab is the generic name for the trade name drugs Prolia or Xgeva.
  • http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Tre...
  • Denosumab is a targeted therapy used to treat secondary bone cancer.
  • 1 2 3 4 5 6 7 8 9

    News

    Healthier bones and less recurrence with denosumab
    Nature - Thursday, March 7, 2019
    ONJ Rare After Dental Work While on Denosumab for Osteoporosis
    Medscape - Tuesday, February 26, 2019
    Adjuvant Denosumab Improved DFS in HR+ Breast Ca
    Medpage Today - Tuesday, February 26, 2019
    Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women
    Physicians Briefing - Wednesday, February 20, 2019
    Study Quantifies Dental, Jaw Risks With Denosumab
    Medpage Today - Wednesday, February 20, 2019
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study
    Nature - Thursday, November 29, 2018
    Can Rare Rebound Fractures After Denosumab Therapy Be Avoided? Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?
    Med Worm - Tuesday, October 23, 2018
    ASBMR: High-Dose Forteo Plus Prolia Increased BMD
    Medpage Today - Monday, October 8, 2018
    New Denosumab Indication; Seafood & Fertility; World Thyroid Day
    Medpage Today - Monday, May 28, 2018
    Benefits, Drawbacks to Denosumab Tx in ESRD
    Medpage Today - Friday, April 13, 2018
    FDA Approves Xgeva for Prevention of Skeletal Events In Multiple Myeloma
    P&T Community - Wednesday, January 10, 2018
    Bisphosphonates and denosumab for breast cancer
    Cochrane - Tuesday, October 31, 2017
    Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
    Nature - Wednesday, October 11, 2017
    Prolia Benefits Persist to a Decade in Postmenopausal Women
    Medpage Today - Monday, September 11, 2017
    Denosumab (Prolia) Subcutaneous Injection
    RXList - Wednesday, August 23, 2017
    Single Shot of Zoledronate Doesn't Preserve BMD After Denosumab
    RXList - Monday, August 7, 2017
    Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
    Nature - Tuesday, June 13, 2017
    Osteoporosis: ACP update treatment guidelines for preventing bone fractures In revised guidelines, the ACP strongly advise that women with osteoporosis should be treated with bisphosphonates or denosumab to prevent bone fractures. 644.51
    Medical News Today - Thursday, May 11, 2017
    MORE NEWS

    Videos

    Prolia Medication Overview
         
    Prolia is a prescription medication used to treat osteoporosis. http://www.rxwiki.com/Prolia

    Prolia Medication Overview
           
    Prolia is a prescription medication used to treat osteoporosis. http://www.rxwiki.com/Prolia

    Xgeva Approved to Treat Patients with Giant Cell Tumor of the Bone
           
    http://www.rxwiki.com/fda-alerts/xgeva-approved-treat-patients-giant-cell-tumor-bone The FDA has expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancer...

    Bone Rx Boosts Breast Cancer Survival
           
    www.rxwiki.com Nearly all postmenopausal women with early-stage, HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures. For this reason, high-risk patients ar...

    Scrip Awards 2010: Best New Drug - Amgen's Prolia (denosumab)
           
    Jeremy Haigh, VP International Chief Operating Officer for R&D, Amgen: "I am delighted and honoured that for the second consecutive eyar, Amgen has been seen its indusry peers to have the best new drug, and I think that really shows that we are able to d...

    Managing Bone Health in Breast Cancer
           
    Panelist discuss the efficacy of denosumab and zoledronic acid, which are both currently approved to help reduce the incidence of skeletal-related events in patients with breast cancer.

    A discussion with Dr. Lesley Fallowfield, San Antonio Breast Cancer Symposium 2010
           
    San Antonio Breast Cancer Symposium 2010 - A discussion with Dr. Lesley Fallowfield, Professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex, UK on The Effect of Treatment with Denosumab or Zoledronic Acid on Health-Related ...

    AUA 2011 Prostate Cancer News
           
    Sally Church, PhD from Pharma Strategy Blog shares news from AUA 2011, the annual meeting of the American Urological Association in Washington, DC. Sally focuses on new therapies for advanced prostate cancer including abiraterone (Zytiga), MDV3100, zoled...

    EAU 2011 Vienna Conference report by Pharma Strategy Blog
           
    Sally Church, PhD from Pharma Strategy Blog provides perspective on the changing landscape for prostate cancer treatment that today offers new hope to patients. She provides insight on the March 2011 European Association of Urology annual congress in Vien...

    Images

    prolia 8
    prolia 7
    prolia 6
    prolia 5
    prolia 4
    prolia 8
    wikidoc.org
    prolia 7
    drugs.com
    prolia 6
    drugs.com
    prolia 5
    drugs.com
    prolia 4
    drugs.com
    prolia 3
    prolia 2
    prolia 1
    xgeva 03
    xgeva 01
    prolia 3
    drugs.com
    prolia 2
    drugs.com
    prolia 1
    drugs.com
    xgeva 03
    drugs.com
    xgeva 01
    drugs.com
    Prolia is specifically used for women at high risk of breaking bones. (iStock)
    Xgeva Generates Survival Benefit in Postmenopausal Women With Breast Cancer
    Over 90% of patients with metastatic prostate cancer have bone metastases, and the vast majority of these patients develop bone pain from the metastases during the course of the disease.[1] All such patients should be treated with zoledronic acid and/or d
    Denosumab panel 01.png
    Denosumab clinical studies 02
    Prolia is specifically used for women at high risk of breaking bones. (iStock)
    cbc.ca
    Xgeva Generates Survival Benefit in Postmenopausal Women With Breast Cancer
    curetoday.com
    Over 90% of patients with metastatic prostate cancer have bone metastases, and the vast majority of these patients develop bone pain from the metastases during the course of the disease.[1] All such patients should be treated with zoledronic acid and/or d
    obgyn.net
    Denosumab panel 01.png
    wikidoc.org
    Denosumab clinical studies 02
    wikidoc.org
    Denosumab adverse 01
    Denosumab administration 04
    Denosumab administration 03
    Denosumab administration 01
    prolia 7
    Denosumab adverse 01
    wikidoc.org
    Denosumab administration 04
    wikidoc.org
    Denosumab administration 03
    wikidoc.org
    Denosumab administration 01
    wikidoc.org
    prolia 7
    druglib.com
    prolia 7
    print xgeva program
    print xgeva action
    xgeva 1
    prolia 6
    prolia 7
    rxlist.com
    print xgeva program
    xgeva.com
    print xgeva action
    xgeva.com
    xgeva 1
    rxlist.com
    prolia 6
    rxlist.com
    prolia 5
    prolia 4
    prolia 3
    prolia 2
    prolia 1
    prolia 5
    rxlist.com
    prolia 4
    rxlist.com
    prolia 3
    rxlist.com
    prolia 2
    rxlist.com
    prolia 1
    rxlist.com
    Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting
    os denosumab vs zoledronic acid 300x 213
    Prolia
    Prolia
    Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting
    news-medical.net
    os denosumab vs zoledronic acid 300x 213
    cancergrace.org
    Prolia
    pharmacytimes.com
    Prolia
    osteoporosistreatment.co.uk
    "Prolia binds RankL preventing RankL-induced activation of osteoclasts.
    healthcentral.com
    Prolia (denosumab) is also indicated for bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
    Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts
    Given as a subcutaneous injection twice a year, denosumab inhibits the RANK ligand - a key regulator of bone-resorbing osteoclasts.
    The Food and Drug Administration recently approved the drug Prolia (denosumab) for use in treating osteoporosis in postmenopausal women.
    Xgeva is given by subcutaneous injection every four weeks
    Prolia (denosumab) is also indicated for bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
    mims.co.uk
    Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts
    mims.co.uk
    Given as a subcutaneous injection twice a year, denosumab inhibits the RANK ligand - a key regulator of bone-resorbing osteoclasts.
    mims.co.uk
    The Food and Drug Administration recently approved the drug Prolia (denosumab) for use in treating osteoporosis in postmenopausal women.
    spine-health.com
    Xgeva is given by subcutaneous injection every four weeks
    mims.co.uk

    MORE IMAGES